AGAPE ATP CORPORATION Finance Lease, Liability, Current
AGAPE ATP CORPORATION (ATPC) had Finance Lease, Liability, Current of $14.72 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2026-08-14
- 2026-06-30: Finance Lease, Liability, Current $14.72K.
- 2026-03-31: Finance Lease, Liability, Current $25.91K.
- 2025-12-31: Finance Lease, Liability, Current $14.48K; Finance Lease, Liability, Current as first filed $25.34K.
- 2025-09-30: Finance Lease, Liability, Current $23.99K.
| Period end | Finance Lease, Liability, Current | Finance Lease, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $14.72K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $25.91K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $14.48K 10-Q · filed 2026-08-14 | $25.34K 10-K · filed 2026-04-13 |
| 2025-09-30 | $23.99K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $23.55K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $22.13K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $21.64K 10-K · filed 2026-04-13 | |
| 2024-09-30 | $23.09K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $8.24K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $8.05K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $7.08K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |